Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | KDM5A | P29375 | 1/20 | 0.41 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.41 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.41 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.40 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.40 |
| ▸ | EGLN1 | Q9GZT9 | 2/20 | 0.39 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.39 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.39 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.39 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.39 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.39 |
| ▸ | FLT1 | P17948 | 1/20 | 0.39 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.39 |
| ▸ | KDR | P35968 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 3/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | SETDB1 | Q15047 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | GLA | P06280 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30088460 | 1.00 | HTT (0.44) | HTTKDM5AKDM4CKDM5BMRGPRX4 | |
| SCHEMBL15752905 | 0.86 | PDCD1 (0.45) | KDM5AKDM4CKDM5BMRGPRX4FFAR1 | |
| SCHEMBL30088492 | 0.86 | PDCD1 (0.45) | KDM5AKDM4CKDM5BMRGPRX4FFAR1 | |
| SCHEMBL28994234 | 0.84 | EGLN1 (0.44) | HTTEGLN1FFAR1FFAR4MAPT | |
| SCHEMBL23832283 | 0.83 | AR (0.42) | HTTMAPTALDH1A1CYP3A4GAA | |
| SCHEMBL14810013 | 0.83 | P2RX7 (0.47) | HTTMRGPRX4FLT1KDRMAPT | |
| SCHEMBL31292267 | 0.83 | HTT (0.40) | HTTEGLN1FFAR1MAPTALDH1A1 | |
| SCHEMBL30154472 | 0.83 | AR (0.42) | HTTMAPTALDH1A1CYP3A4GAA | |
| SCHEMBL6072554 | 0.83 | ALDH1A1 (0.44) | HTTEGLN1MAPTALDH1A1KDM4E | |
| SCHEMBL30154498 | 0.83 | FFAR1 (0.46) | HTTEGLN1FFAR1FFAR4CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230227426-A1 | PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND USE | AKEBIA THERAPEUTICS, INC. (US) | 2023-07-20 | — | — | US | disclosed |
| US-20230227426-A1 | PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND USE | AKEBIA THERAPEUTICS, INC. (US) | 2023-07-20 | — | — | US | disclosed |
| US-20230212138-A1 | PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND THEIR USE | AKEBIA THERAPEUTICS, INC. (US) | 2023-07-06 | — | — | US | disclosed |
| US-20230212138-A1 | PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND THEIR USE | AKEBIA THERAPEUTICS, INC. (US) | 2023-07-06 | — | — | US | disclosed |
| EP-4121424-A1 | PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND THEIR USE | Akebia Therapeutics Inc. (US) | 2023-01-25 | — | — | EP | disclosed |
| EP-4121425-A1 | PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND USE | Akebia Therapeutics Inc. (US) | 2023-01-25 | — | — | EP | disclosed |
| CN-115605467-A | PHD inhibitor compounds, compositions and uses thereof | 阿克比治疗有限公司（US） | 2023-01-13 | — | — | CN | disclosed |
| CN-115551845-A | PHD inhibitor compounds, compositions and uses | 阿克比治疗有限公司 | 2022-12-30 | — | — | CN | disclosed |
| EP-3476829-B1 | BIARYL UREA DERIVATIVE OR SALT THEREOF, AND MANUFACTURING AND APPLICATION OF SAME | UNIV FUDAN (CN) | 2021-12-15 | — | — | EP | disclosed |
| WO-2021188944-A1 | PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND THEIR USE | AKEBIA THERAPEUTICS, INC. (US) | 2021-09-23 | — | — | WO | disclosed |
| US-10647665-B2 | Biaryl urea derivative or salt thereof and preparation process and use for the same | FUDAN UNIVERSITY (CN) | 2020-05-12 | — | — | US | disclosed |
| US-20190248737-A1 | BIARYL UREA DERIVATIVE OR SALT THEREOF AND PREPARATION PROCESS AND USE FOR THE SAME | FUDAN UNIVERSITY (CN) | 2019-08-15 | — | — | US | disclosed |
| EP-3476829-A1 | BIARYL UREA DERIVATIVE OR SALT THEREOF, AND MANUFACTURING AND APPLICATION OF SAME | Fudan University (CN) | 2019-05-01 | — | — | EP | disclosed |
| US-20140163026-A1 | 8-ETHYL-6-(ARYL)PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONES FOR THE TREATMENT OF NERVOUS SYSTEM DISORDERS AND CANCER | AFRAXIS HOLDINGS, INC. (US) | 2014-06-12 | — | — | US | disclosed |
| US-20140163026-A1 | 8-ETHYL-6-(ARYL)PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONES FOR THE TREATMENT OF NERVOUS SYSTEM DISORDERS AND CANCER | AFRAXIS HOLDINGS, INC. (US) | 2014-06-12 | — | — | US | disclosed |
| EP-2694504-A2 | 8-ETHYL-6-(ARYL)PYRIDO [2,3-D]PYRIMIDIN-7(8H)-ONES FOR THE TREATMENT OF NERVOUS SYSTEM DISORDERS AND CANCER | Afraxis Holdings, Inc. (US) | 2014-02-12 | — | — | EP | disclosed |
| WO-2013043232-A2 | 8-ETHYL-6-(ARYL)PYRIDO [2,3-D]PYRIMIDIN-7(8H) -ONES FOR THE TREATMENT OF NERVOUS SYSTEM DISORDERS AND CANCER | AFRAXIS, INC. (US) | 2013-03-28 | — | — | WO | disclosed |
| WO-2013043232-A2 | 8-ETHYL-6-(ARYL)PYRIDO [2,3-D]PYRIMIDIN-7(8H) -ONES FOR THE TREATMENT OF NERVOUS SYSTEM DISORDERS AND CANCER | AFRAXIS, INC. (US) | 2013-03-28 | — | — | WO | disclosed |
| US-7465811-B2 | Indoline compounds | LABORATOIRES FOURNIER S.A. (FR) | 2008-12-16 | — | — | US | disclosed |
| US-20080119465-A1 | Novel Indoline Compounds | LABORATORIES FOURNIER S.A. (FR) | 2008-05-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080119465-A1 | Novel Indoline Compounds | GPR119, INSR, IRS1 | HTT 36/4885KDM5A 2026/4885KDM4C 2225/4885 |
| US-20230227426-A1 | PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND USE | HIF1AN, EGLN3, PHF20 | HTT 3527/4885KDM5A 72/4885KDM4C 161/4885 |
| US-20190248737-A1 | BIARYL UREA DERIVATIVE OR SALT THEREOF AND PREPARATION PROCESS AND USE FOR THE SAME | RORC, RORB, RORA | HTT 2402/4885KDM5A 2203/4885KDM4C 2434/4885 |
| US-10647665-B2 | Biaryl urea derivative or salt thereof and preparation process and use for the same | RORC, RORB, RORA | HTT 2402/4885KDM5A 2203/4885KDM4C 2434/4885 |
| US-20230212138-A1 | PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND THEIR USE | HIF1AN, EGLN3, EGLN2 | HTT 3875/4885KDM5A 99/4885KDM4C 224/4885 |
| US-20140163026-A1 | 8-ETHYL-6-(ARYL)PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONES FOR THE TREATMENT OF NERVOUS SYSTEM DISORDERS AND CANCER | PAK2, PAK1, PAK6 | HTT 2459/4885KDM5A 2004/4885KDM4C 1978/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.